Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| First Candidate From SCYNEXIS' Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof Of Concept In ... (Medical News Today) |
 |
 |
|
Drug discovery company, SCYNEXIS, Inc., announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma HCV RNA. |
